182 related articles for article (PubMed ID: 30149225)
1. Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer.
Bense RD; Qiu SQ; de Vries EGE; Schröder CP; Fehrmann RSN
Cancer Treat Rev; 2018 Nov; 70():118-126. PubMed ID: 30149225
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF
Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
[TBL] [Abstract][Full Text] [Related]
3. The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.
Van Asten K; Poppe A; Punie K; Jongen L; Lintermans A; Wildiers H; Neven P
Curr Treat Options Oncol; 2015 Jul; 16(7):31. PubMed ID: 26031545
[TBL] [Abstract][Full Text] [Related]
4. Extended endocrine therapy in premenopausal breast cancer patients: Where are we now?
Villasco A; D'Alonzo M
Breast J; 2020 Oct; 26(10):2018-2020. PubMed ID: 32468640
[TBL] [Abstract][Full Text] [Related]
5. Current controversies in extended adjuvant endocrine therapy for early breast cancer.
Snoj N; Paridaens R; Cufer T
Curr Opin Oncol; 2008 Nov; 20(6):627-33. PubMed ID: 18841043
[TBL] [Abstract][Full Text] [Related]
6. The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Pennery E
Eur J Oncol Nurs; 2008 Jul; 12(3):233-43. PubMed ID: 18372213
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
Mayer EL; Burstein HJ
Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133
[TBL] [Abstract][Full Text] [Related]
8. Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?
Walsh EM; Nunes R; Wilkinson MJ; Santa-Maria CA
Curr Oncol Rep; 2020 Oct; 22(12):123. PubMed ID: 33015752
[TBL] [Abstract][Full Text] [Related]
9. Extended endocrine therapy in early breast cancer: how long and who for?
Benson JR; Jatoi I
Future Oncol; 2020 Jan; 16(1):4327-4336. PubMed ID: 31802715
[TBL] [Abstract][Full Text] [Related]
10. Extended Endocrine Therapy: Is 5 Years Enough?
Bhave MA; Henry NL
Curr Oncol Rep; 2017 Mar; 19(3):16. PubMed ID: 28251491
[TBL] [Abstract][Full Text] [Related]
11. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
12. Advances in adjuvant endocrine therapy for postmenopausal women.
Lin NU; Winer EP
J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
[TBL] [Abstract][Full Text] [Related]
13. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
14. Predicting benefit of endocrine therapy for early breast cancer.
Regan MM
Breast; 2015 Nov; 24 Suppl 2(0 2):S129-31. PubMed ID: 26255197
[TBL] [Abstract][Full Text] [Related]
15. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Chlebowski RT
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
[TBL] [Abstract][Full Text] [Related]
16. Overcoming recurrence risk: extended adjuvant endocrine therapy.
Cianfrocca M
Clin Breast Cancer; 2008 Dec; 8(6):493-500. PubMed ID: 19073503
[TBL] [Abstract][Full Text] [Related]
17. Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Bedard PL; Piccart-Gebhart MJ
Curr Opin Oncol; 2009 Nov; 21(6):491-8. PubMed ID: 19593135
[TBL] [Abstract][Full Text] [Related]
18. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
19. The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?
Smith IE; Yeo B; Schiavon G
Am Soc Clin Oncol Educ Book; 2014; ():e16-24. PubMed ID: 24857098
[TBL] [Abstract][Full Text] [Related]
20. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
